Veru announces successful fda meeting providing regulatory clarity for enobosarm for muscle preservation in combination with glp-1 ra for greater weight loss in the treatment of obesity

Miami, fl, sept. 23, 2025 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced a successful meeting with fda providing regulatory clarity for enobosarm, a selective androgen receptor modulator, as a muscle preservation drug product candidate in combination with glp-1 ra for greater weight loss for the treatment of obesity.
VERU Ratings Summary
VERU Quant Ranking